Avidity Biosciences (RNAM)

RNAM was delisted on the 26th of February, 2026.

• Market cap: $11.2B
• Sector: Healthcare
• Industry: Biotechnology

About: Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Employees: 391